Group items tagged

According to Alzheimer's Disease International, more than 55 million people worldwide will have Alzheimer's disease by 2020. This figure will nearly double every 20 years, reaching 78 million in 2030 and 139 million in 2050. The WHO Global Status Report for 2021 estimated the yearly global cost of dementia to be more than USD 1.3 trillion, with a projected increase to USD 2.8 trillion by 2030. To date most drugs developed to treat Alzheimer's disease have failed, largely because they target wrong biomarkers and individuals already exhibiting signs of the disease. Once symptoms appear, however, many brain cells responsible for memory and cognition are likely already damaged and beyond repair. Professor Shai Rahimipour in the Chemistry Department at Bar-Ilan University in Israel has pioneered a different approach utilizing theranostics to pinpoint and treat the earliest, pre-symptomatic signs of Alzheimer's disease. Showing promise in stopping progression of the disease before onset of irreversible brain cell damage, Rahimipour's groundbreaking approach has garnered significant attention in the scientific world.

The National Health Service (NHS) on Monday launched a new national campaign to find the 'missing millions' who could be living with undiagnosed high blood pressure, often described as a 'silent killer'. People are being warned that the condition rarely has any symptoms and it can lead to fatal heart attacks, strokes, kidney disease and vascular dementia, if left untreated. According to the NHS, high blood pressure affects an estimated 32 per cent of adults and approximately three in 10 of these remain undiagnosed, equating to 4.2 million people in England. The NHS has expanded blood pressure checks in community pharmacies to include 2.5 million more tests as part of the Pharmacy First programme. With the 'Get Your Blood Pressure Checked' campaign, the health service is encouraging those aged 40 years and over to get a free blood pressure test at a participating pharmacy, for which they don't need to be booked in advance. Health Minister Andrea Leadsom expressed confidence that this new drive will help to prevent the potentially "fatal consequences" of untreated high blood pressure. She urged people to go to their local pharmacy to get their blood pressure checked, stating that it could be a "lifesaving trip."

In a new study, men who took phosphodiesterase type 5 inhibitors (PDE5Is), such as Viagra (sildenafil; Pfizer), for treatment of erectile dysfunction, were found to be 18 per cent less likely to develop Alzheimer's compared to those who did not take the drugs. The results of the population-based cohort study were published in Neurology on 7 February 2024. Researchers at University of Oxford examined IQVIA Medical Research Data UK records of 269,725 men, who were diagnosed with erectile dysfunction between January 2000 and March 2017. None of the participants had any memory or thinking problems at the start of the study and they were followed for an average of 5.1 years. During the study, 749 out of 1,119 participants taking erectile dysfunction drugs developed Alzheimer's disease.

This is a very long newsletter. I will answer questions about oil versus water-soluble Vitamin D, depression, mental clarity, malignant melanoma, Crohn's disease, an imagist poet, multiple sclerosis, sun-exposure, high-intensity red light and collagen repair in the skin, non-alcoholic fatty liver disease, influenza, the 1918 influenza pandemic, statins, the new Food and Nutrition Board, thyroid disease, chronic fatigue syndrome, athletes, the upcoming 14th Vitamin D Workshop, prostate cancer, the wrong blood test, pregnancy, autism, Alzheimer's disease, soap and sebum, asthma, sleep, the co-factors vitamin D needs to work (all contained in spinach), and-my favorite-UVC light and Vitamin D

Omega 3 fatty acids are important fats that provide many health benefits. Studies have found that they may reduce inflammation, decrease blood triglycerides and even reduce the risk of dementia. The most well-known sources of omega-3 fatty acids include fish oil and fatty fish like salmon, trout and tuna.

The first big breakthrough in 30 years of Alzheimer's research is providing momentum for clinical trials of "cocktail" treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives. Drugmakers Eisai and Biogen reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo. The finding validates the theory that clearing the amyloid protein that forms clumps in the brains of Alzheimer's patients could slow or halt the disease and has strengthened the support from some scientists for simultaneously targeting another notorious protein linked to Alzheimer's: tau. Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. The U.S. Food and Drug Administration is expected to make a decision by early January on the companies' application for accelerated approval. If approved on an accelerated basis, the companies said they would immediately apply for full U.S. regulatory approval which could help secure Medicare coverage.